LT3856341T - (s)-1-(4-fluorfenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f] [1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amino kristalinės formos ir gamybos būdai - Google Patents

(s)-1-(4-fluorfenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f] [1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amino kristalinės formos ir gamybos būdai

Info

Publication number: LT3856341T
Authority: LT; Lithuania
Prior art keywords: ethan; triazin; pyrrolo; pyrazol; pyrimidin
Prior art date: 2019-04-12

Application number

LTEPPCT/US2020/027724T

Other languages

English (en)

Inventor

Joshua WAETZIG

Brenton MAR

Brian HEINRICH

Gordon Wilkie

Lauren MACEACHERN

Original Assignee

Blueprint Medicines Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-04-12

Filing date

2020-04-10

Publication date

2023-12-27

2020-04-10 Application filed by Blueprint Medicines Corporation filed Critical Blueprint Medicines Corporation

2023-12-27 Publication of LT3856341T publication Critical patent/LT3856341T/lt

Links

DWYRIWUZIJHQKQ-SANMLTNESA-N (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine Chemical compound Cn1cc(cn1)-c1cc2c(ncnn2c1)N1CCN(CC1)c1ncc(cn1)[C@@](C)(N)c1ccc(F)cc1 DWYRIWUZIJHQKQ-SANMLTNESA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

LTEPPCT/US2020/027724T 2019-04-12 2020-04-10 (s)-1-(4-fluorfenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f] [1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amino kristalinės formos ir gamybos būdai LT3856341T (lt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201962833527P	2019-04-12	2019-04-12
US201962844575P	2019-05-07	2019-05-07
US202062990269P	2020-03-16	2020-03-16
PCT/US2020/027724 WO2020210669A1 (en)	2019-04-12	2020-04-10	Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making

Publications (1)

Publication Number	Publication Date
LT3856341T true LT3856341T (lt)	2023-12-27

Family

ID=70476546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/US2020/027724T LT3856341T (lt)	2019-04-12	2020-04-10	(s)-1-(4-fluorfenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f] [1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amino kristalinės formos ir gamybos būdai

Country Status (18)

Country	Link
US (4)	US20210147433A1 (lt)
EP (2)	EP3856341B1 (lt)
JP (1)	JP2022526438A (lt)
CN (1)	CN113966334A (lt)
CA (1)	CA3136707A1 (lt)
DK (1)	DK3856341T3 (lt)
ES (1)	ES2966512T3 (lt)
FI (1)	FI3856341T3 (lt)
HR (1)	HRP20231533T1 (lt)
HU (1)	HUE064283T2 (lt)
IL (1)	IL287148A (lt)
LT (1)	LT3856341T (lt)
MA (1)	MA53759A (lt)
PL (1)	PL3856341T3 (lt)
PT (1)	PT3856341T (lt)
RS (1)	RS64881B1 (lt)
SI (1)	SI3856341T1 (lt)
WO (1)	WO2020210669A1 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105658652B (zh)	2013-10-17	2019-04-12	蓝图药品公司	可用于治疗与kit相关的病症的组合物
MA53759A (fr)	2019-04-12	2021-08-04	Blueprint Medicines Corp	Formes cristallines de (s)-1-(4-fluorophényl)-1-(2-(4-(6-(1-méthyl-1h-pyrazol-4-yl))pyrrolo[2,1-f][1,2,4]triazin-4-yl)pipérazinyl)-pyrimidin-5-yl)éthan-1-amine et des procédés de fabrication
EP3997090A1 (en) *	2019-07-09	2022-05-18	Sandoz AG	Crystalline forms of an orally available, selective kit and pdgfr kinase inhibitor
GB201915447D0 (en) *	2019-10-24	2019-12-11	Johnson Matthey Plc	Polymorphs of avapritinib and methods of preparing the polymorphs
WO2021183709A1 (en)	2020-03-11	2021-09-16	Teva Czech Industries S.R.O	Solid state forms of avapritinib and process for preparation thereof
EP4168119A1 (en)	2020-06-17	2023-04-26	Teva Czech Industries s.r.o.	Solid state forms of avapritinib salts
HU231413B1 (hu) *	2021-02-26	2023-08-28	Egis Gyógyszergyár Zrt.	Eljárás avapritinib és intermedierek előállítására
WO2022187477A1 (en)	2021-03-03	2022-09-09	Blueprint Medicines Corporation	Synthetic methods and intermediates for producing compounds for treating kit- and pdgfra-mediated diseases
HUP2200323A1 (hu) *	2022-08-11	2024-02-28	Egyt Gyogyszervegyeszeti Gyar	Új avapritinib sók és elõállítási eljárásaik

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61238784A (ja)	1985-04-17	1986-10-24	Sumitomo Seiyaku Kk	コハク酸イミド誘導体及びその酸付加塩
US6982265B1 (en)	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
ES2328269T3 (es)	1999-05-21	2009-11-11	Bristol-Myers Squibb Company	Pirrolotriazinas como inhibires de quinasas.
WO2001025220A1 (en)	1999-10-07	2001-04-12	Amgen Inc.	Triazine kinase inhibitors
SE0102616D0 (sv)	2001-07-25	2001-07-25	Astrazeneca Ab	Novel compounds
HUE025353T2 (en)	2002-04-23	2016-02-29	Bristol Myers Squibb Co	Pyrrolo-triazine aniline compounds as kinase inhibitors
TW200508224A (en)	2003-02-12	2005-03-01	Bristol Myers Squibb Co	Cyclic derivatives as modulators of chemokine receptor activity
AR043416A1 (es)	2003-02-27	2005-07-27	Uriach Y Compania S A J	Un compuesto que comprende derivados de pirazolopiridina, procedimiento para preparar dicho compuesto y sus usos en la manufactura de medicamentos y composiciones farmaceuticas
CA2563699C (en)	2004-04-23	2014-03-25	Exelixis, Inc.	Kinase modulators and method of use
EP1755607A2 (en)	2004-04-29	2007-02-28	Pharmix Corporation	Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20050288290A1 (en)	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
US7439246B2 (en)	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US8431695B2 (en)	2005-11-02	2013-04-30	Bayer Intellectual Property Gmbh	Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7348325B2 (en)	2005-11-30	2008-03-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
PT1973910E (pt)	2006-01-27	2013-09-06	Shanghai Hengrui Pharm Co Ltd	Inibidores de pirrolo [3,2-c] piridina-4-ona 2-indolinona proteína cinase
ES2493566T3 (es)	2006-07-07	2014-09-12	Bristol-Myers Squibb Company	Inhibidores de pirrolotriazina quinasa
ES2392003T3 (es)	2007-07-25	2012-12-03	Bristol-Myers Squibb Company	Inhibidores de la triazina quinasa
CA2716856C (en)	2008-03-20	2013-02-19	Amgen Inc.	Aurora kinase modulators and method of use
KR20100003912A (ko)	2008-07-02	2010-01-12	삼성전자주식회사	동일 포맷의 미디어 파일 간에 미디어 정보 호환이 가능한미디어 파일을 생성하는 방법 및 장치와 미디어 파일을실행하는 방법 및 장치
WO2010022055A2 (en)	2008-08-20	2010-02-25	Amgen Inc.	Inhibitors of voltage-gated sodium channels
AU2010259009A1 (en)	2009-06-08	2012-01-12	Nantbioscience, Inc.	Triazine derivatives and their therapeutical applications
DK3072890T3 (en)	2009-07-07	2019-02-11	Mei Pharma Inc	Pyrimidinyl and 1,3,5-triazinylbenzimidazoles and their use in cancer therapy
MX2012009561A (es)	2010-02-17	2012-11-23	Amgen Inc	Carboxamidas como inhibidores de canales de sodio dependientes del voltaje.
US8609672B2 (en)	2010-08-27	2013-12-17	University Of The Pacific	Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102040494A (zh)	2010-11-12	2011-05-04	西北师范大学	对氟苯甲醛的制备方法
PL2872491T3 (pl)	2012-07-11	2021-12-13	Blueprint Medicines Corporation	Inhibitory receptora czynnika wzrostu fibroblastów
CN104981247A (zh)	2012-09-06	2015-10-14	普莱希科公司	用于激酶调节的化合物和方法及其适应症
MX365640B (es)	2012-12-21	2019-06-10	Plexxikon Inc	Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
TWI629266B (zh)	2012-12-28	2018-07-11	藍印藥品公司	纖維母細胞生長因子受體之抑制劑
WO2014160521A1 (en)	2013-03-15	2014-10-02	Blueprint Medicines Corporation	Piperazine derivatives and their use as kit modulators
WO2015058129A1 (en)	2013-10-17	2015-04-23	Blueprint Medicines Corporation	Compositions useful for treating disorders related to kit
CN105658652B (zh)	2013-10-17	2019-04-12	蓝图药品公司	可用于治疗与kit相关的病症的组合物
JP6458023B2 (ja)	2013-10-25	2019-01-23	ブループリントメディシンズコーポレイション	繊維芽細胞成長因子受容体の阻害剤
WO2015108992A1 (en)	2014-01-15	2015-07-23	Blueprint Medicines Corporation	Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2016022569A1 (en)	2014-08-04	2016-02-11	Blueprint Medicines Corporation	Compositions useful for treating disorders related to kit
US10202365B2 (en)	2015-02-06	2019-02-12	Blueprint Medicines Corporation	2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
KR20180048635A (ko)	2015-07-24	2018-05-10	블루프린트 메디신즈 코포레이션	Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물
MX2018002407A (es)	2015-08-26	2018-11-29	Blueprint Medicines Corp	Compuestos y composiciones utiles para tratar trastornos relacionados con ntrk.
US20170119760A1 (en)	2015-10-28	2017-05-04	Ab Science	Use of masitinib for the treatment of progressive supranuclear palsy
MY194262A (en)	2015-11-02	2022-11-25	Blueprint Medicines Corp	Inhibitors of ret
US10370379B2 (en)	2015-11-19	2019-08-06	Blueprint Medicines Corporation	Compounds and compositions useful for treating disorders related to NTRK
US10183928B2 (en)	2016-03-17	2019-01-22	Blueprint Medicines Corporation	Inhibitors of RET
KR102426043B1 (ko)	2016-04-15	2022-07-27	블루프린트 메디신즈 코포레이션	액티빈 수용체 유사 키나아제의 저해제
WO2018017983A1 (en)	2016-07-22	2018-01-25	Blueprint Medicines Corporation	Compounds useful for treating disorders related to ret
US10035789B2 (en)	2016-07-27	2018-07-31	Blueprint Medicines Corporation	Compounds useful for treating disorders related to RET
WO2018049233A1 (en)	2016-09-08	2018-03-15	Nicolas Stransky	Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
US11040979B2 (en)	2017-03-31	2021-06-22	Blueprint Medicines Corporation	Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN109400610A (zh)	2017-08-18	2019-03-01	浙江海正药业股份有限公司	吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
CN108191874B (zh)	2018-01-16	2019-11-29	成都施贝康生物医药科技有限公司	一种C-Kit抑制剂及其应用
CN111886006B (zh) *	2018-01-31	2024-07-09	德西费拉制药有限责任公司	治疗肥大细胞增多症的组合疗法
WO2020102095A1 (en)	2018-11-12	2020-05-22	Blueprint Medicines Corporation	Avapritinib resistance of kit mutants
MA53759A (fr)	2019-04-12	2021-08-04	Blueprint Medicines Corp	Formes cristallines de (s)-1-(4-fluorophényl)-1-(2-(4-(6-(1-méthyl-1h-pyrazol-4-yl))pyrrolo[2,1-f][1,2,4]triazin-4-yl)pipérazinyl)-pyrimidin-5-yl)éthan-1-amine et des procédés de fabrication
EP3997090A1 (en)	2019-07-09	2022-05-18	Sandoz AG	Crystalline forms of an orally available, selective kit and pdgfr kinase inhibitor
GB201915447D0 (en)	2019-10-24	2019-12-11	Johnson Matthey Plc	Polymorphs of avapritinib and methods of preparing the polymorphs
EP4054587A1 (en) *	2019-11-04	2022-09-14	Blueprint Medicines Corporation	Treatment of mast cell diseases and eosinophilic disorders
CN110950872A (zh)	2019-12-25	2020-04-03	武汉九州钰民医药科技有限公司	制备靶向抗癌药avapritinib的方法
CN110938077B (zh)	2019-12-25	2021-04-27	武汉九州钰民医药科技有限公司	合成Avapritinib的方法

2020
- 2020-04-10 MA MA053759A patent/MA53759A/fr unknown
- 2020-04-10 EP EP20722936.0A patent/EP3856341B1/en active Active
- 2020-04-10 DK DK20722936.0T patent/DK3856341T3/da active
- 2020-04-10 RS RS20231131A patent/RS64881B1/sr unknown
- 2020-04-10 PT PT207229360T patent/PT3856341T/pt unknown
- 2020-04-10 CN CN202080042782.9A patent/CN113966334A/zh active Pending
- 2020-04-10 ES ES20722936T patent/ES2966512T3/es active Active
- 2020-04-10 HR HRP20231533TT patent/HRP20231533T1/hr unknown
- 2020-04-10 PL PL20722936.0T patent/PL3856341T3/pl unknown
- 2020-04-10 HU HUE20722936A patent/HUE064283T2/hu unknown
- 2020-04-10 JP JP2021560265A patent/JP2022526438A/ja active Pending
- 2020-04-10 FI FIEP20722936.0T patent/FI3856341T3/fi active
- 2020-04-10 CA CA3136707A patent/CA3136707A1/en active Pending
- 2020-04-10 LT LTEPPCT/US2020/027724T patent/LT3856341T/lt unknown
- 2020-04-10 SI SI202030328T patent/SI3856341T1/sl unknown
- 2020-04-10 WO PCT/US2020/027724 patent/WO2020210669A1/en active Application Filing
- 2020-04-10 EP EP23195076.7A patent/EP4302761A3/en active Pending
2021
- 2021-01-20 US US17/153,727 patent/US20210147433A1/en active Pending
- 2021-10-10 IL IL287148A patent/IL287148A/en unknown
2022
- 2022-12-08 US US18/077,431 patent/US20230124801A1/en active Pending
- 2022-12-08 US US18/077,466 patent/US11964980B2/en active Active
2023
- 2023-12-18 US US18/543,793 patent/US11999744B2/en active Active

Also Published As

Publication number	Publication date
CN113966334A (zh)	2022-01-21
US20230271971A1 (en)	2023-08-31
CA3136707A1 (en)	2020-10-15
EP3856341B1 (en)	2023-09-06
US11999744B2 (en)	2024-06-04
HRP20231533T1 (hr)	2024-03-01
US20240132510A1 (en)	2024-04-25
US20230124801A1 (en)	2023-04-20
RS64881B1 (sr)	2023-12-29
PT3856341T (pt)	2023-12-12
HUE064283T2 (hu)	2024-02-28
IL287148A (en)	2021-12-01
PL3856341T3 (pl)	2024-03-04
US11964980B2 (en)	2024-04-23
SI3856341T1 (sl)	2024-02-29
EP4302761A3 (en)	2024-03-27
MA53759A (fr)	2021-08-04
WO2020210669A1 (en)	2020-10-15
EP4302761A2 (en)	2024-01-10
DK3856341T3 (da)	2023-12-04
EP3856341A1 (en)	2021-08-04
FI3856341T3 (fi)	2023-11-30
TW202104232A (zh)	2021-02-01
US20210147433A1 (en)	2021-05-20
ES2966512T3 (es)	2024-04-22
JP2022526438A (ja)	2022-05-24

Publication	Publication Date	Title
IL287148A (en)	2021-12-01	Crystal forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[1,2-f][4, 2,1]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods for preparation
CO2021017366A2 (es)	2022-01-17	Formas en estado sólido
MX2021014235A (es)	2022-03-11	Formas en estado sólido.
MX2020011250A (es)	2022-09-08	Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
NZ628186A (en)	2016-03-31	Compounds for treating spinal muscular atrophy
NZ611151A (en)	2015-06-26	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
ZA202003483B (en)	2023-01-25	5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
PH12020551639A1 (en)	2021-07-05	Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
EP4092024A4 (en)	2024-03-13	HETEROCYCLIC COMPOUND OF PYRIMIDINE-4(3H)-KETONE, METHOD FOR PREPARING IT AND ITS USE IN MEDICINE AND PHARMACOLOGY
EA202090450A1 (ru)	2020-09-24	Антагонисты рецептора кортикотропин-рилизинг фактора
MX2021012849A (es)	2022-02-24	Una 7-h-pirrolo[2,3-d]pirimidina inhibidora de jak.
WO2005065266A8 (en)	2005-11-17	Di-substituted pyrrolotriazine compounds
EP3560931A4 (en)	2020-05-13	METHOD FOR PRODUCING A 7H-PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE, AND CO-CRYSTAL OF SAID DERIVATIVE
MX353041B (es)	2017-12-18	Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y métodos de este.
MX2020012540A (es)	2021-02-16	Uso de inhibidor de cdk4/6 en combinacion con inhibidor del egfr en la preparacion de medicamento para tratar enfermedades tumorales.
PH12021551180A1 (en)	2022-02-14	Methods of treating myeloproliferative disorders
MX2021010131A (es)	2021-11-18	Formas sólidas de pirazinas condensadas a manera de inhibidores de syk.
MX2019000159A (es)	2019-05-30	Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]pirida zin-4-onas como inhibidores de la proteina quinasa.
EP4045506A4 (en)	2023-08-30	4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL)PYRIMIDINE-2-AMINE DERIVATIVES FOR TREATMENT OF PROLIFERATIVE DISEASES AND CONDITIONS
EA201990940A1 (ru)	2019-10-31	ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EP4161522A4 (en)	2024-06-26	PYRAZOLO [4,3-D]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS
MX2023004591A (es)	2023-07-06	Inhibidores de janus cinasas (jak) que tienen una distribución de tamaño de partícula específica.
MX2021012310A (es)	2021-11-12	Formulación de secado por aspersión de un inhibidor de trpc5 de piridazinona.
AU2017903306A0 (en)	2017-08-31	DERIVATIVES OF 4-(IMIDAZO[1,2-b]PYRIDAZIN-3-YL) PYRIMIDIN-2-AMINE AND THEIR USE AS INHIBITORS OF PROTEIN KINASES
UA81420C2 (en)	2008-01-10	Process for the preparation of substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase